Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that occur either in relatively rare, familial forms or in common, sporadic forms. The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear. To gain insights into the pathogenic mechanisms involved in AD and PD, we used a proteomic approach to identify proteins with altered expression levels and/or oxidative modifications in idiopathic AD and PD brains. Here, we report that the protein level of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), a neuronal de-ubiquitinating enzyme whose mutation has been linked to an early-onset familial PD, is down-regulated in idiopathic PD as well as AD brains. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified three human brain UCH-L1 isoforms, a full-length form and two amino-terminally truncated forms. Our proteomic analyses reveal that the full-length UCH-L1 is a major target of oxidative damage in AD and PD brains, which is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation. Furthermore, immunohistochemical studies show that prominent UCH-L1 immunostaining is associated with neurofibrillary tangles and that the level of soluble UCH-L1 protein is inversely proportional to the number of tangles in AD brains. Together, these results provide evidence supporting a direct link between oxidative damage to the neuronal ubiquitination/de-ubiquitination machinery and the pathogenesis of sporadic AD and PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dysfunction contributes to neuronal damage and death by several mechanisms, including ER stress and the accumulation of oxidatively damaged proteins, which in the normal brain are usually degraded by the UPS and autophagy to keep their levels low8,50,53,55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“a crucial part of the UPS is oxidatively damaged and dysfunctional in both aMCI and AD brain, namely, ubiquitin carboxyl-terminal hydrolase L-1 (UCH L1)34,55–57.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“the failure of oxidatively damaged UCH L1 to perform its function in aMCI and AD brains leads to accumulation of ubiquitinylated proteins, decreased proteasome function, and subsequent accumulation of damaged, aggregated proteins55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Roepstorff, P., & Fohlman, J. (1984) · Biological Mass Spectrometry · doi:10.1002/bms.1200111109 · Cited by 2,633
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Oxidant signals and oxidative stress
Finkel, T. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00002-4 · Cited by 1,393
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Methionine residues as endogenous antioxidants in proteins
Levine, R. L., Mosoni, L., Berlett, B. S., & Stadtman, E. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15036 · Cited by 1,041
The Neuron-Specific Protein PGP 9.5 Is a Ubiquitin Carboxyl-Terminal Hydrolase
Wilkinson, K. D., Lee, K., Deshpande, S., Duerksen-Hughes, P., Boss, J. M., & Pohl, J. (1989) · Science · doi:10.1126/science.2530630 · Cited by 871
Research works printed but not linked: 2
- Ischiropoulos, 2003, J. Clin. Invest., 111, 163, 10.1172/jci200317638 · DOI · Paper page
- Wu, 1996, Alzheimer's Res., 2, 163
Cited by
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
“Indeed, this fall in UCHL1 activity involves oxidative damage, because the protein shows raised levels of carbonyls and methionine sulfoxide (Choi et al. 2004).”
BackgroundInfluentialOxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat
Carrieri, C., Cimatti, L., Biagioli, M., Beugnet, A., Zucchelli, S., Fedele, S., Pesce, E., Ferrer, I., Collavin, L., Santoro, C., et al. (2012) · Nature · doi:10.1038/nature11508 · Cited by 1,000
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 835
“Since both UCH-L1 and DJ-1 contain a cysteine residue that is important for their activity [12, 13] and their oxidative modification at cysteine has been observed in PD [14, 15], the DA quinone modification is likely the cause of inactivation of these enzymes.”
BackgroundPINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1
Pridgeon, J. W., Olzmann, J. A., Chin, L.-S., & Li, L. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050172 · Cited by 596
“Protein bands were excised from the membrane, digested by trypsin, and analyzed by nanoelectrospray tandem mass spectrometry as described previously [30,31].”
Self-citationButterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.037 · Cited by 564
“These results further support the hypothesis that oxidative stress is a mediator of synaptic loss and a presumed factor for the formation of neurofibrillary tangles and senile plaques [10,12,13,37,38,98,199].”
ResultOxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., Gearing, M., Levey, A. I., Chin, L.-S., & Li, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509079200 · Cited by 483
Self-citationMitochondrial Dysfunction in Parkinson’s Disease
Moon, H. E., & Paek, S. H. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.2.103 · Cited by 455
“Moreover, inactivating oxidative modifications of this protein have been reported in PD post-mortem brains where it correlates with the formation of protein aggregates [42], and UCH-L1 together with parkin and α-synuclein are the major components of LB [43].”
BackgroundDeubiquitylases From Genes to Organism
Clague, M. J., Barsukov, I., Coulson, J. M., Liu, H., Rigden, D. J., & Urbé, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00002.2013 · Cited by 425
“A proteomic analysis has revealed that UCHL1 is a major target of oxidative damage in Alzheimer’s disease (AD) and idiopathic PD brains (35).”
BackgroundGong, B., Cao, Z., Zheng, P., Vitolo, O. V., Liu, S., Staniszewski, A., Moolman, D., Zhang, H., Shelanski, M., & Arancio, O. (2006) · Cell · doi:10.1016/j.cell.2006.06.046 · Cited by 420
Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications
Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel-Daim, M. M., & Stankiewicz, A. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00004 · Cited by 395
“UCHL1 protein co-localizes with NFTs in AD brains (Choi et al., 2004).”
BackgroundAutophagy as an essential cellular antioxidant pathway in neurodegenerative disease
Giordano, S., Darley-Usmar, V., & Zhang, J. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.013 · Cited by 366
Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis
Dasuri, K., Zhang, L., & Keller, J. N. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.016 · Cited by 371
Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach
Sultana, R., Poon, H. F., Cai, J., Pierce, W. M., Merchant, M., Klein, J. B., Markesbery, W. R., & Butterfield, D. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.10.004 · Cited by 364
Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics
Butterfield, D. A., Perluigi, M., & Sultana, R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.026 · Cited by 363
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
Sanders, L. H., & Timothy Greenamyre, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.003 · Cited by 345
“Interestingly, carbonyl formation and methionine and cysteine oxidation occur on UCH-L1 in idiopathic PD [94].”
Type 2 diabetes as a protein misfolding disease
Mukherjee, A., Morales-Scheihing, D., Butler, P. C., & Soto, C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.005 · Cited by 342
Fish, docosahexaenoic acid and Alzheimer’s disease
Cunnane, S. C., Plourde, M., Pifferi, F., Bégin, M., Féart, C., & Barberger-Gateau, P. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.04.001 · Cited by 317
“In post-mortem brain samples from AD patients, oxidative damage can be observed in the form of oxidized lipids, proteins and DNA [55].”
BackgroundSultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., Markesbery, W. R., & Butterfield, D. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.021 · Cited by 335
“There is accumuating evidence that oxidative stress plays an important role in AD pathophysiology.”
BackgroundDysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
Zheng, Q., Huang, T., Zhang, L., Zhou, Y., Luo, H., Xu, H., & Wang, X. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00303 · Cited by 311
“In addition, decreased soluble UCHL1 protein levels was detected in the brains of postmortem AD patients and APP/PS1 mouse models (Choi et al., 2004; Gong et al., 2006), and soluble UCHL1 is inversely proportional to the number of NFTs in AD brains (Choi et al.”
BackgroundBishop, P., Rocca, D., & Henley, J. M. (2016) · Biochemical Journal · doi:10.1042/bcj20160082 · Cited by 305
Choi, J., Rees, H. D., Weintraub, S. T., Levey, A. I., Chin, L.-S., & Li, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414327200 · Cited by 291
Self-citationThe functions of UCH-L1 and its relation to neurodegenerative diseases
Setsuie, R., & Wada, K. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.05.007 · Cited by 285
Redox Proteomics: Chemical Principles, Methodological Approaches and Biological/Biomedical Promises
Bachi, A., Dalle-Donne, I., & Scaloni, A. (2013) · Chemical Reviews · doi:10.1021/cr300073p · Cited by 251
Sultana, R., Perluigi, M., & Butterfield, D. A. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.2021 · Cited by 262
Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment
Mangialasche, F., Polidori, M. C., Monastero, R., Ercolani, S., Camarda, C., Cecchetti, R., & Mecocci, P. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.002 · Cited by 248
“…levels in the brain (Hensley et al., 1995; Lyras et al., 1997; Aksenova et al., 1999; Lauderback et al., 2001; Castegna et al., 2002a, 2002b; Choi et al., 2004; Keller et al., 2005; Pamplona et al., 2005; Sultana et al., 2006a, 2006b), plasma and peripheral blood cells (Calabrese et al.,…”
Ubiquitin–proteasome system and Parkinson's diseases
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.021 · Cited by 245
The role of survival motor neuron protein (SMN) in protein homeostasis
Chaytow, H., Huang, Y.-T., Gillingwater, T. H., & Faller, K. M. E. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2849-1 · Cited by 217
Butterfield, D. A., Reed, T. T., Perluigi, M., De Marco, C., Coccia, R., Keller, J. N., Markesbery, W. R., & Sultana, R. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.084 · Cited by 236
“Nitric oxide (NO) reacting with the superoxide anion (O2U−) forms the product, peroxynitrite (ONOO−), known to lead to nitration of tyrosine (3-NT) residues (Butterfield and Kanski, 2001; Gow et al., 1996).”
BackgroundlncRNAs: Insights into their function and mechanics in underlying disorders
Li, X., Wu, Z., Fu, X., & Han, W. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.04.002 · Cited by 232
“Parkinson’s disease as well as Alzheimer’s disease [149].”
BackgroundProteomics Analysis of the Alzheimer's Disease Hippocampal Proteome
Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., & Butterfield, D. A. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11203 · Cited by 230
Role of Iron in Neurodegenerative Disorders
Berg, D., & Youdim, M. B. H. (2006) · Topics in Magnetic Resonance Imaging · doi:10.1097/01.rmr.0000245461.90406.ad · Cited by 226
Kurup, P., Zhang, Y., Xu, J., Venkitaramani, D. V., Haroutunian, V., Greengard, P., Nairn, A. C., & Lombroso, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0157-10.2010 · Cited by 224
“Deubiquitinating enzymes that promote the degradation of accumulated proteins are downregulated in brains of AD mouse models and patients (Choi et al., 2004), whereas restoring ubiquitin-recycling enzymes rescues memory deficits and dendritic spine alterations in the AD mouse models (Gong et al.”
BackgroundKabuta, T., Furuta, A., Aoki, S., Furuta, K., & Wada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801918200 · Cited by 227
Berg, D., Youdim, M. B. H., & Riederer, P. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 220
Martínez, A., Portero‐Otin, M., Pamplona, R., & Ferrer, I. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00326.x · Cited by 213
“Reference Disease/stage Protein Function Detection antibody Degree of oxidation in relation to age-matched controls Enzymatic activity Total protein levels Comments Reed et al (100) AD MCI Braak stages III, IV, V, VI Hippocampus Anti-HNE antibody Neuropolypeptide h3 Phospholipid binding protein ↑ NA NA — Carbonyl redu…”
BackgroundMethodInfluentialSultana, R., Perluigi, M., & Butterfield, D. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0517-0 · Cited by 215
Mitochondrial dysfunction, oxidative stress and neurodegeneration
Mancuso, M., Coppede, F., Migliore, L., Siciliano, G., & Murri, L. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10110 · Cited by 208
Cell death: protein misfolding and neurodegenerative diseases
Nakamura, T., & Lipton, S. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0301-y · Cited by 189
“For example, S-nitrosylation and further oxidation of parkin or Uch-L1 result in dysfunction of these enzymes and thus of the UPS [17, 18, 121–124].”
Bilguvar, K., Tyagi, N. K., Ozkara, C., Tuysuz, B., Bakircioglu, M., Choi, M., Delil, S., Caglayan, A. O., Baranoski, J. F., Erturk, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222732110 · Cited by 189
“In addition to these genetic data, UCHL1’s expression has been shown to be down-regulated in the brains of patients with both Parkinson and Alzheimer’s diseases (25).”
BackgroundRegulation of proteolysis by human deubiquitinating enzymes
Eletr, Z. M., & Wilkinson, K. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.027 · Cited by 183
“In humans UCH-L1 is found in neurofibrillary tangles of Alzheimer’s disease patients [111] and is down regulated and oxidatively inactivated in brains of Alzheimer’s and Parkinson’s disease patients [112].”
BackgroundFerrer, I., Martinez, A., Blanco, R., Dalfó, E., & Carmona, M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0482-8 · Cited by 192
“Moreover, some of them appear to be modified by oxidation thus resulting in lost of function (Choi et al. 2004; Chung et al. 2004; see later).”
BackgroundThe Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease
Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190
“That is, in areas where NFTs formed abundantly, including hippocampus and parahippocampal gyrus and superior and middle temporal gyri, proteasome activity (as assessed by chymortrypsinlike and postglutamyl peptidases) appeared to be most affected, whereas occipital gyri and cerebellum, which often have few or no NFTs,…”
BackgroundInfluentialRole of the ubiquitin proteasome system in Alzheimer's disease
Upadhya, S. C., & Hegde, A. N. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s12 · Cited by 186
“Full-length UCHL1 appears to be a major target of oxidative damage in AD and PD brains, and the enzyme is extensively modified by carbonyl formation, methionine oxidation and cysteine oxidation [44].”
BackgroundUbiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications
Huang, Q., & Figueiredo-Pereira, M. E. (2010) · Apoptosis · doi:10.1007/s10495-010-0466-z · Cited by 172
“In addition to mutations, UCH-L1 is a major contributor to idiopathic AD and PD [129].”
Gong, B., Radulovic, M., Figueiredo-Pereira, M. E., & Cardozo, C. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00004 · Cited by 165
The Ubiquitin-Proteasome System in Neurodegeneration
McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 165
“analyses revealed a reduction in wild-type UCH-L1 levels in post-mortem AD and PD brains, and identified that the protein is a major target of oxidative damage (28, 37).”
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
“…to quite a variety of substrates including mitochondrial and energy metabolism-related proteins (Butterfield et al., 2002; Castegna et al., 2002a,b; Choi et al., 2004, 2005; Pamplona et al., 2005; Korolainen et al., 2006; Sultana et al., 2006, 2009; Reed et al., 2008; Sultana and Butterfield,…”
BackgroundSwomley, A. M., & Butterfield, D. A. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1556-z · Cited by 170
“These results were corroborated by others who also found oxidatively modified Cu/Zn-superoxide dismutase (Choi et al. 2004).”
ResultRedox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications
Butterfield, D. A., Perluigi, M., Reed, T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Sultana, R. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 168
“UCH-L1 was found to be carbonylated protein in AD brain or by Ab(1–42) (50, 91, 103).”
Boyd-Kimball, D., Sultana, R., Fai Poon, H., Lynn, B. C., Casamenti, F., Pepeu, G., Klein, J. B., & Butterfield, D. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.022 · Cited by 166
“Others, using proteomics, confirmed our findings (Castegna et al., 2002a) that ubiquitin carboxyl-terminal hydrolase L-1 is an oxidized protein in AD brain ( Choi et al., 2004 ).”
Proteome analysis of human substantia nigra in Parkinson's disease
Werner, C. J., Heyny-von Haussen, R., Mall, G., & Wolf, S. (2008) · Proteome Science · doi:10.1186/1477-5956-6-8 · Cited by 167
“On the other hand, Choi and colleagues [26] described oxidative modifications and a decrease of UCHL1 in frontal cortex of PD patients.”
BackgroundZhang, Q., Ma, C., Gearing, M., Wang, P. G., Chin, L.-S., & Li, L. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0524-2 · Cited by 165
“Each experiment was repeated three times with similar results DJ-1, APOE, clusterin (CLU), and UCH-L1 [1, 17, 19, 55].”
Self-citationRelationship between amyloid-beta and the ubiquitin–proteasome system in Alzheimer’s disease
Hong, L., Huang, H.-C., & Jiang, Z.-F. (2014) · Neurological Research · doi:10.1179/1743132813y.0000000288 · Cited by 159
Protein carbonylation and metabolic control systems
Curtis, J. M., Hahn, W. S., Long, E. K., Burrill, J. S., Arriaga, E. A., & Bernlohr, D. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.05.008 · Cited by 189
“For instance, the abundant de-ubiquitylating enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is highly susceptible to oxidative modification [51].”
BackgroundPeriquet, M., Corti, O., Jacquier, S., & Brice, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03442.x · Cited by 160
“…identified in several proteomic analyses on brains from patients affected by schizophrenia, Down’s syndrome or Alzheimer’s disease (Schonberger et al. 2001; Castegna et al. 2002a, 2002b; Choi et al. 2004a; Tilleman et al. 2002a, 2002b; Kadota et al. 2004; Prabakaran et al. 2004; Jin et al. 2005).”
BackgroundResultKung, H., Lin, K.-J., Kung, C., & Lin, T. (2021) · Biomedicines · doi:10.3390/biomedicines9080918 · Cited by 180
The circular RNA ci RS‐7 promotes APP and BACE 1 degradation in an NF‐κB‐dependent manner
Shi, Z., Chen, T., Yao, Q., Zheng, L., Zhang, Z., Wang, J., Hu, Z., Cui, H., Han, Y., Han, X., et al. (2017) · The FEBS Journal · doi:10.1111/febs.14045 · Cited by 157
Van Laar, V. S., Mishizen, A. J., Cascio, M., & Hastings, T. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.03.004 · Cited by 152
Synaptic Therapy in Alzheimer's Disease: A CREB-centric Approach
Teich, A. F., Nicholls, R. E., Puzzo, D., Fiorito, J., Purgatorio, R., Fà, M., & Arancio, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0327-5 · Cited by 166
“In addition, Uch-L1 is downregulated in AD brains [36].”
BackgroundJeong, A., Suazo, K. F., Wood, W. G., Distefano, M. D., & Li, L. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1458070 · Cited by 146
“The same proteomic technique led to the identification of UCHL1 as a major target of oxidative damage in AD (Castegna et al. 2002; Choi et al. 2004).”
MethodSelf-citationMillan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 153
Gu, Z., Nakamura, T., & Lipton, S. A. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8113-9 · Cited by 151
Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications
Fang, Y., & Shen, X. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9702-0 · Cited by 154
“Previous studies focused on the role of UCHL1 in neurodegenerative disorders, particularly in Parkinson’s disease (PD) and Alzheimer’s disease (AD) [34, 36, 50, 51].”
Regulation of Synaptic Structure by Ubiquitin C-Terminal Hydrolase L1
Cartier, A. E., Djakovic, S. N., Salehi, A., Wilson, S. M., Masliah, E., & Patrick, G. N. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1817-09.2009 · Cited by 141
“UCH-L1 is also commonly found in the neurofibrillary tangles observed in Alzheimer’s Disease (AD) brains in which the levels of soluble UCH-L1 are decreased (Choi et al., 2004).”
Chen, F., Sugiura, Y., Myers, K. G., Liu, Y., & Lin, W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911516107 · Cited by 136
“In addition, UCH-L1 undergoes oxidative modification in AD (11, 12) and PD (12), and its expression is down-regulated in sporadic AD and PD (12).”
BackgroundLiu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A., Cookson, M., Liu, Y., Logan, T., & Lansbury, P. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806474106 · Cited by 141
Target Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 142
Zhang, M., Cai, F., Zhang, S., Zhang, S., & Song, W. (2014) · Scientific Reports · doi:10.1038/srep07298 · Cited by 135
Role of 4-Hydroxynonenal-Protein Adducts in Human Diseases
Barrera, G., Pizzimenti, S., Ciamporcero, E. S., Daga, M., Ullio, C., Arcaro, A., Cetrangolo, G. P., Ferretti, C., Dianzani, C., Lepore, A., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.6166 · Cited by 130
“concerned the oxidation of cysteinyl and methionyl residues (35, 36, 37).”
Rubino, T., Realini, N., Braida, D., Alberio, T., Capurro, V., Viganò, D., Guidali, C., Sala, M., Fasano, M., & Parolaro, D. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9031-3 · Cited by 146
“A disruption in the expression of these proteins could promote degenerative changes, in fact it was found a loss of function of HSC71 and/or UCHL1 in the brains of Alzheimer’s disease and/or Parkinson’s disease patients (Castegna et al. 2002a, b; Choi et al. 2004; Boyd-Kimball et al. 2005; Butterfield et al. 2006; Set…”
BackgroundDefective Autophagy in Parkinson’s Disease: Role of Oxidative Stress
Janda, E., Isidoro, C., Carresi, C., & Mollace, V. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8318-1 · Cited by 140
“UCH-L1 activity can be impaired by oxidative modifications, which can occur in sporadic forms of PD in response to oxidative stress [91].”
BackgroundThe Intertwining of Transposable Elements and Non-Coding RNAs
Hadjiargyrou, M., & Delihas, N. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713307 · Cited by 145
“Uch1 is a neuron associated protein in mammals and may be involved in neurological disease formation [37,38].”
BackgroundDi Domenico, F., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schinina, M. E., Mancuso, C., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.013 · Cited by 134
“The incubation with MG 132 was performed 30 min before addition of the proteasome substrate.”
MethodCorsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Khatri, D. K., & Juvekar, A. R. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.09.002 · Cited by 141
The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim?
Dennissen, F. J. A., Kholod, N., & van Leeuwen, F. W. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.01.003 · Cited by 144
“patients (Choi et al., 2004).”
Carrieri, C., Forrest, A. R. R., Santoro, C., Persichetti, F., Carninci, P., Zucchelli, S., & Gustincich, S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00114 · Cited by 126
The Neuroproteomics of Schizophrenia
English, J. A., Pennington, K., Dunn, M. J., & Cotter, D. R. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.031 · Cited by 127
Perluigi, M., Di Domenico, F., Barone, E., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.04.025 · Cited by 121
Butterfield, D. A., & Sultana, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12107 · Cited by 126
Costes, S., Huang, C.-J., Gurlo, T., Daval, M., Matveyenko, A. V., Rizza, R. A., Butler, A. E., & Butler, P. C. (2011) · Diabetes · doi:10.2337/db10-0522 · Cited by 124
“In neurons from individuals with Alzheimer’s or Parkinson’s disease, UCH-L1 protein expression is decreased and is also a major target of oxidative damage (24).”
BackgroundMethionine-35 of A β (1–42): Importance for Oxidative Stress in Alzheimer Disease
Butterfield, D. A., & Sultana, R. (2011) · Journal of Amino Acids · doi:10.4061/2011/198430 · Cited by 124
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
The potential role of ubiquitin c-terminal hydrolases in oncogenesis
Fang, Y., Fu, D., & Shen, X. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.03.001 · Cited by 125
Chaperone-mediated autophagy. Machinery, regulation and biological consequences
Li, W., Yang, Q., & Mao, Z. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0565-6 · Cited by 119
“Mutant forms of UCH-L1 are associated with familial PD [88].”
BackgroundChondrogianni, N., Voutetakis, K., Καπετάνου, Μ., Delitsikou, V., Papaevgeniou, N., Sakellari, M., Lefaki, M., Filippopoulou, K., & Gonos, E. S. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.003 · Cited by 127
Quan, Z., Zheng, D., & Qing, H. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00175 · Cited by 120
“UCHL1 gene mutations have been discovered to be related to familial PD, and the oxidative inactivation of Uchl1 protein has been reported in PD and AD brains (Choi et al., 2004; Barrachina et al., 2006).”
BackgroundRedox Control of Platelet Function
Essex, D. W. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2322 · Cited by 113
Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6759 · Cited by 114
Verrastro, I., Pasha, S., Jensen, K., Pitt, A., & Spickett, C. (2015) · Biomolecules · doi:10.3390/biom5020378 · Cited by 114
“Untargeted MS/MS approaches have been used to provide evidence of irreversible cysteine oxidation in different proteins in brain tissue of patients with Alzheimer’s or Parkinson’s diseases [137,161,166].”
MethodKhanna, R., Wilson, S. M., Brittain, J. M., Weimer, J., Sultana, R., Butterfield, A., & Hensley, K. (2012) · Future Neurology · doi:10.2217/fnl.12.68 · Cited by 110
Hashimoto, M., & Hossain, S. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10r33fm · Cited by 127
Setsuie, R., Wang, Y.-L., Mochizuki, H., Osaka, H., Hayakawa, H., Ichihara, N., Li, H., Furuta, A., Sano, Y., Sun, Y., et al. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.015 · Cited by 127
The role of the ubiquitin proteasome system in Alzheimer's disease
Riederer, B. M., Leuba, G., Vernay, A., & Riederer, I. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010327 · Cited by 110
Butterfield, D. A., Di Domenico, F., Swomley, A. M., Head, E., & Perluigi, M. (2014) · Biochemical Journal · doi:10.1042/bj20140772 · Cited by 113
Grimm, S., Hoehn, A., Davies, K. J., & Grune, T. (2011) · Free Radical Research · doi:10.3109/10715762.2010.512040 · Cited by 107
Penke, B., Bogár, F., Crul, T., Sántha, M., Tóth, M. E., & Vígh, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010325 · Cited by 122
“In parallel, the inducibility and chaperon activity of Hsps are impaired during aging (reviewed in [55]) which is accompanied by a reduced activity of the protein degradation systems as well [144].”
BackgroundRole of UCHL1 in the pathogenesis of neurodegenerative diseases and brain injury
Mi, Z., & Graham, S. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101856 · Cited by 121
The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition
Steele, M. L., Stuchbury, G., & Münch, G. W. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.002 · Cited by 123
“Oxidative damage can be observed in post-mortem brain tissues from AD patients in the form of oxidized proteins, lipids and DNA (Choi et al., 2004).”
Background
Metadata
- Authors
- Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L.
- Affiliations
- Emory University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Li, Lian
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 13
- Pages
- 13256-13264
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2169393803
- Cited by
- 568
- References
- 38
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 20 · 2021: 36 · 2020: 16 · 2019: 16 · 2018: 22 · 2017: 28 · 2016: 24 · 2015: 26 · 2014: 34 · 2013: 29 · 2012: 30
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG010130, AG-10130, AG021489, R01AG021489)
- National Cancer Institute (P30CA054174, CA-54174)
- National Institute of Neurological Disorders and Stroke (NS-047199, R01NS047199)
- National Institute of Environmental Health Sciences (ES-12068, U54ES012068)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- UCHL1, Parkinson's disease, Alzheimer's disease, protein oxidation, carbonylation, methionine oxidation, cysteine oxidation, deubiquitination, neurofibrillary tangles, protein downregulation, brain proteome
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Brain, Chromatography, High Pressure Liquid, Coloring Agents, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Molecular Sequence Data, Mutation, Oxygen, Parkinson Disease, Mass Spectrometry, Trypsin, Immunoblotting, Electrophoresis, Gel, Two-Dimensional, Down-Regulation, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Oxidative Stress, Protein Isoforms, Proteome, Ubiquitin Thiolesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.